AngioDynamics Inc. reported unaudited consolidated earnings results for the second quarter and six months ended November 30, 2012. For the quarter, net sales were $87,007,000 against $58,099,000 a year ago. Operating income was $5,122,000 against $3,926,000 a year ago. Income before income taxes was $3,132,000 against $3,569,000 a year ago. Net income was $1,969,000 or $0.06 per basic and diluted share against $2,329,000 or $0.09 per basic and diluted share a year ago. Adjusted net income was $3,581,000 or $0.10 per diluted share against $2,768,000 or $0.11 per diluted share a year ago. EBITDA was $11,414,000 or $0.32 per diluted share against $7,067,000 or $0.28 per diluted share a year ago. Adjusted EBITDA was $13,791,000 or $0.39 per diluted share against $7,756,000 or $0.31 per diluted share a year ago. Adjusted operating income was $7,499,000 against $4,615,000 a year ago. Net cash provided by operating activities was $11,130,000 against $2,669,000 a year ago. Additions to property, plant and equipment was $3,819,000 against $517,000 a year ago.

For the six months, net sales were $170,423,000 against $112,530,000 a year ago. Operating income was $5,806,000 against $6,643,000 a year ago. Income before income taxes was $1,978,000 against $5,672,000 a year ago. Net income was $1,248,000 or $0.04 per basic and diluted share against $3,702,000 or $0.15 per basic and diluted share a year ago. Adjusted net income was $7,164,000 or $0.20 per diluted share against $3,658,000 or $0.14 per diluted share a year ago. EBITDA was $17,967,000 or $0.51 per diluted share against $12,916,000 or $0.51 per diluted share a year ago. Adjusted EBITDA was $27,010,000 or $0.77 per diluted share against $12,872,000 or $0.51 per basic and diluted share a year ago. Adjusted operating income was $14,849,000 against $6,599,000 a year ago. Net cash provided by operating activities was $5,515,000 against $5,713,000 a year ago. Additions to property, plant and equipment was $4,787,000 against $1,058,000 a year ago.

For the full year of 2013, the company expects to report sales between $355 million to $360 million, gross margin between $50% to 51%, operating income between $29 million to $31 million, EBITDA between $56 million to $57 million and EPS between $0.40 to 0.42.